MedTrace Logo

Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting

NCT01405248 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-10-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether butylphthalide are effective for Preventing Restenosis after Intracranial and Extracranial Artery Stenting

Conditions

  • Restenosis

Interventions

DRUG

Butylphthalide

20 mg/time per os three times a day. 180days

DRUG

Placebo

20 mg/time per os three times a day. 180days

Sponsors & Collaborators

  • CSPC-NBP Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Jinling Hospital, China

    lead OTHER

Principal Investigators

  • Xinfeng Liu, MD · Department of Neurology, Jinling Hospital, Nanjing University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01405248 on ClinicalTrials.gov